AstraZeneca Antibody Therapy Prevents Infection, the study found

AstraZeneca announced this Friday (20) that its antibody therapy has achieved the key goal of preventing Govit-19, paving the way for the British pharmaceutical company to offer an alternative route to people with vulnerable systems. Immune systems.

The company claims that a cocktail of two types of antibodies, first discovered by the University of Vanderbilt University Medical Center in the United States, has reduced the risk of developing symptomatic Covid-19 by 77%.

Astrogeneca explained that more than 75% of participants had chronic problems, some associated with a weakened immune response to the vaccine.

The results bring relief to the drugmaker, who announced in June that a low-level testing, antibody cocktail, now known as AZD7442, provided no evidence that it protected people infected with the new corona virus.

The Anglo-Swedish company is facing challenges in distributing its Govt-19 vaccine and working to modify existing drugs to fight the virus.